Table 3.
Chemotherapy data collected from relevant articles for three main parasitic diseases in China
| Disease | Article (n) |
Clinical trial for MOH Recommended drug |
Drug development |
|||||
|---|---|---|---|---|---|---|---|---|
| Drug’s name (n) | Cure rates (%) | Population | Labwork (n) | Clinical trial (n) | Basic science | Marketization | ||
| Malaria |
51* |
Dihydroartemisinin (31) |
70%-100% |
104 (15–1205) |
50 |
0 |
50/50 |
0/50 |
| Artemether (30) |
79.8%-100% |
|||||||
| Piperaquine (19) |
80%-100% |
|||||||
| Artesunate (18) |
90.7%-100% |
|||||||
| Chloroquine (9) |
62.8%-100% |
|||||||
| Primaquine (9) |
85.5%-100% |
|||||||
| Artemether-lumefantrine (1) |
82.50% |
|||||||
| Schistosomiasis |
22 |
Praziquantel (22) |
74.7%-100% |
221 (33–615) |
42 |
0 |
42/42 |
0/42 |
| Echinococcosis | 11* | Albendazole emulsion (7) |
57.1%-83.1% |
95 (36–264) |
11 | 9 | 11/20 | 9/20 |
| Albendazole tablet (6) | 15.8%-31.3% | 57 (24–108) | ||||||
* More than one kind of drug can be studied in one article.